Lymphatic Filariasis Clinical Trial
Official title:
Effect of Albendazole and Ivermectin Dose on Wuchereria Bancrofti Microfilarial Clearance in Mali: A Randomized, Open Label Study
Verified date | August 17, 2011 |
Source | National Institutes of Health Clinical Center (CC) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study, conducted in Mali, West Africa, will determine whether a new treatment regimen
for lymphatic filariasis can eliminate the disease more quickly than the standard regimen.
Lymphatic filariasis is caused by infection with very small filarial worms called Wuchereria
bancrofti that are spread by mosquitoes. The disease can cause swelling of the arms, legs,
breast and genitalia and can progress to permanent swelling of the legs or arms called
elephantiasis. Currently, patients in Mali are treated with a single dose of 400 mg of
albendazole plus two doses of 200 mcg/kg of ivermectin each year. This study will use a
regimen of 800 mg of albendazole twice a year plus 200 mcg/kg of ivermectin twice a year for
2 years. The study will see if the new regimen is more effective in lowering the numbers of
Wuchereria bancrofti in the blood and will examine the effects of the two treatments on the
adult worms living in the lymph system.
Healthy people between 14 and 65 years of age who live in the Mali village of N'Tessoni and
are infected with Wuchereria bancrofti may be eligible for this study. Candidates are
screened with a medical history, a brief physical examination and blood tests to check for
infection with Wuchereria bancrofti and to measure white blood cell counts.
Participants undergo the following procedures:
-First visit
Ultrasound examination to look for filarial worms in the body.
Random assignment to receive either standard treatment or the experimental regimen
Urine pregnancy test for women of child-bearing age.
Receive first treatment dose.
-6-month visit
Short history, physical examination and blood test.
Second treatment dose for subjects in experimental treatment group.
Urine pregnancy test for women of childbearing age.
-1-year visit
Short history, physical examination and blood test.
Second or third treatment dose, depending on treatment group.
Repeat ultrasound in subjects whose first ultrasound detected adult worms.
Urine pregnancy test for women of childbearing age.
-18-month visit
Short history, physical examination and blood test.
Fourth treatment dose for subjects in experimental treatment group.
Urine pregnancy test for women of childbearing age.
-24-month visit
Short history, physical examination and blood test.
Repeat ultrasound in subjects whose first ultrasound detected adult worms.
Urine pregnancy test for women of childbearing age.
Status | Completed |
Enrollment | 1000 |
Est. completion date | August 17, 2011 |
Est. primary completion date | August 1, 2008 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 14 Years to 65 Years |
Eligibility |
- INCLUSION CRITERIA (Screening): - age 14 to 65. - men and women*. - Please note: women are not permitted to leave their homes at night without the approval of their husband or, if they are not married, a parent or male guardian. Since this protocol involves blood drawing at night, such approval is necessary for participation. EXCLUSION CRITERIA (Screening): - non-volunteers. - age less than 14 or greater than 65. - pregnant by history. INCLUSION CRITERIA (Treatment): - age 14 to 65 years. - men and women.* - Wb microfilarial count greater than or equal to 50 mf/ml. EXCLUSION CRITERIA (Treatment): - non-volunteers. - age less than 14 or greater than 65. - pregnancy. - Hgb less than 9 g/dl. - Heavy alcohol use (more than 7 beer or other alcohol-containing drink/week). - Temperature greater than 37.5C or other serious medical illnesses. - history of benzimidazole allergy. - history of ivermectin allergy. - use of albendazole or ivermectin within the past 6 months. |
Country | Name | City | State |
---|---|---|---|
Mali | University of Bamako, Faculty of Medicine, Pharmacy and Odontostomatology | Bamako |
Lead Sponsor | Collaborator |
---|---|
National Institute of Allergy and Infectious Diseases (NIAID) |
Mali,
Addiss DG, Beach MJ, Streit TG, Lutwick S, LeConte FH, Lafontant JG, Hightower AW, Lammie PJ. Randomised placebo-controlled comparison of ivermectin and albendazole alone and in combination for Wuchereria bancrofti microfilaraemia in Haitian children. Lancet. 1997 Aug 16;350(9076):480-4. Erratum in: Lancet 1997 Oct 4;350(9083):1036. — View Citation
Beach MJ, Streit TG, Addiss DG, Prospere R, Roberts JM, Lammie PJ. Assessment of combined ivermectin and albendazole for treatment of intestinal helminth and Wuchereria bancrofti infections in Haitian schoolchildren. Am J Trop Med Hyg. 1999 Mar;60(3):479-86. — View Citation
Horton J, Witt C, Ottesen EA, Lazdins JK, Addiss DG, Awadzi K, Beach MJ, Belizario VY, Dunyo SK, Espinel M, Gyapong JO, Hossain M, Ismail MM, Jayakody RL, Lammie PJ, Makunde W, Richard-Lenoble D, Selve B, Shenoy RK, Simonsen PE, Wamae CN, Weerasooriya MV. An analysis of the safety of the single dose, two drug regimens used in programmes to eliminate lymphatic filariasis. Parasitology. 2000;121 Suppl:S147-60. Review. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Wb microfilarial levels | 12 months | ||
Secondary | Adult worm burden as assessed by circulating antigen levels and visualization of worm nests by ultrasound | 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00375583 -
Effect of Albendazole Dose on Clearance of Filarial Worms
|
Phase 2 | |
Completed |
NCT03664063 -
PK PD Study of IDA and Azithromycin for NTDs ( ComboNTDs )
|
Phase 2 | |
Recruiting |
NCT04844905 -
Adjunctive Ivermectin Mass Drug Administration for Malaria Control
|
Phase 3 | |
Completed |
NCT01975441 -
Eval 3-Drug Therapy Diethylcarbamize, Albendazole and Ivermectin That Could Accelerate LF Elimination Outside of Africa
|
Phase 2 | |
Completed |
NCT01629771 -
Disability and Quality of Life in Patients With Lymphatic Filariasis in Rural Southern India
|
N/A | |
Completed |
NCT01905423 -
Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis
|
||
Completed |
NCT02784743 -
Impact of Albendazole -Ivermectin on Wuchereria Bancrofti in Mali
|
Phase 4 | |
Completed |
NCT03036059 -
Twice Yearly Treatment for the Control of LF
|
Phase 4 | |
Completed |
NCT01905436 -
Mass Drug Administration for Lymphatic Filariasis and Onchocerciasis for Liberia
|
||
Completed |
NCT02509481 -
Repeat Ivermectin Mass Drug Administrations for Control of Malaria: a Pilot Safety and Efficacy Study
|
Phase 2/Phase 3 | |
Completed |
NCT03268252 -
Optimization of MDA With Existing Drug Regimens for LF: Monitoring Efficacy of Ongoing Treatment Programs in PNG
|
||
Completed |
NCT02927496 -
A 24 Month Study, to Compare the Efficacy of Doxycycline vs. Placebo for Improving Filarial Lymphedema in Mali
|
Phase 3 | |
Completed |
NCT02899936 -
Death to Onchocerciasis and Lymphatic Filariasis (DOLF) Triple Drug Therapy for Lymphatic Filariasis
|
N/A | |
Completed |
NCT00511004 -
Effect of Albendazole Dose on Treatment of Lymphatic Filariasis
|
Phase 2 | |
Active, not recruiting |
NCT04258670 -
Spontaneous Antigenemia in Loiasis
|
||
Completed |
NCT02974049 -
Lymphatic Filariasis (LF) in Ivory Coast
|
N/A | |
Terminated |
NCT01213576 -
Efficacy of Higher Albendazole and Ivermectin Doses on Wuchereria Bancrofti Microfilarial Clearance in Malawi
|
N/A | |
Completed |
NCT02929121 -
A 24 Month Study to Compare Efficacy of Doxycycline vs Placebo for Improving Filarial Lymphedema in India
|
Phase 3 | |
Withdrawn |
NCT01903057 -
Safety Study of Combined Azithromycin, Ivermectin and Albendazole for Trachoma and Lymphatic Filariasis
|
Phase 4 | |
Completed |
NCT02032043 -
Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis for Ivory Coast (DOLF-Ivory Coast)
|